Statements (71)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:administered_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:FDA
March 2017 |
| gptkbp:brand |
gptkb:Ocrevus
|
| gptkbp:chemical_formula |
C646 H1008 N178 O198 S4
|
| gptkbp:clinical_trial |
gptkb:OPERA_I
gptkb:OPERA_II Phase III randomized controlled trials observational studies ORATORIO open-label extension studies |
| gptkbp:clinical_use |
disease-modifying therapy
|
| gptkbp:collaborations |
collaborations with academic institutions
partnerships with other pharmaceutical companies |
| gptkbp:competitors |
other MS therapies
|
| gptkbp:contraindication |
active infections
hypersensitivity to ocrelizumab |
| gptkbp:developed_by |
gptkb:Genentech
|
| gptkbp:dosage_form |
solution for infusion
|
| gptkbp:feedback |
generally positive
|
| gptkbp:financial_support |
available patient assistance programs
|
| gptkbp:healthcare |
gptkb:pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
ocrelizumab
|
| gptkbp:indication |
gptkb:primary_progressive_multiple_sclerosis
gptkb:relapsing_forms_of_multiple_sclerosis |
| gptkbp:invention |
2028
|
| gptkbp:is_monitored_by |
regular blood tests required
monitoring for infections required neurological assessments required |
| gptkbp:market_launch |
gptkb:2017
|
| gptkbp:marketed_as |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:mechanism_of_action |
B-cell depletion
|
| gptkbp:patient_education |
important for treatment adherence
|
| gptkbp:patient_population |
adults with multiple sclerosis
|
| gptkbp:pharmacokinetics |
half-life of approximately 26 days
depletes CD20-positive B cells |
| gptkbp:price |
high cost of treatment
|
| gptkbp:provides_guidance_on |
MS treatment guidelines
|
| gptkbp:regulatory_compliance |
approved for use in multiple countries
|
| gptkbp:research |
real-world evidence studies
long-term safety studies comparative effectiveness studies efficacy in pediatric population |
| gptkbp:research_areas |
autoimmune diseases
|
| gptkbp:research_focus |
immunology
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:service_frequency |
every 6 months
|
| gptkbp:side_effect |
fatigue
headache nausea cardiovascular events infections infusion reactions progressive multifocal leukoencephalopathy (PML) risk laboratory abnormalities malignancies risk |
| gptkbp:targets |
CD20 protein
|
| gptkbp:treatment |
improvement in disability scores
reduction in relapse rates reduction in MRI lesions sustained efficacy over time |
| gptkbp:type_of_insurance |
varies by plan
|
| gptkbp:used_for |
treatment of multiple sclerosis
|
| gptkbp:weight |
146 k Da
|
| gptkbp:bfsParent |
gptkb:Ocrevus
|
| gptkbp:bfsLayer |
5
|